+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 75Years
All Genders
ID07850882

Observational Study of Intratumoral Oncolytic Virus Combined with Immune Checkpoint Inhibitors in Metastatic Colorectal, Gastric, and Liver Cancers

Led by Jie Yuan,MD · Updated on 2026-09-30

30

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, feasibility, and early antitumor activity of a combination treatment using an intratumoral oncolytic virus H101 and immune checkpoint inhibitors ICIs in patients with advanced metastatic colorectal cancer, gastric cancer, or hepatocellular carcinoma who have not responded to multiple prior therapies. This single-arm, open-label study also aims to explore how this combination changes the tumors immune environment and to identify potential biomarkers predicting treatment response. Participants receive intratumoral injections of H101 once every 2-3 weeks for four cycles, with the dose based on tumor size. Five to seven days after each H101 injection, they are given intravenous ICIs, either anti-PD-1 alone or combined with anti-CTLA-4 antibodies, according to the physicians choice. Tumor biopsies and blood samples are collected before starting treatment and after the final cycle to analyze immune changes and biomarkers. During the study, participants undergo regular clinical assessments, tumor imaging to evaluate response, and safety monitoring for adverse events. Adverse events are graded using standard criteria from the first dose until 30 days after treatment ends. Tumor responses are measured by established criteria, and progression-free survival is tracked for up to two years. All data are securely managed, and the study follows ethical guidelines with informed consent from all patients.

CONDITIONS

Brief Title

A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)

Research Team

J

Jie Yuan, Doctoral degree

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here